The University of Osaka · Medicine
Professor Yuwei Liu's research lab specializes in targeted radionuclide therapy, with a focus on developing and evaluating novel radiolabeled agents for cancer treatment. The lab investigates alpha- and beta-emitting radionuclides—particularly 211At and 177Lu—for targeted therapy in thyroid and pancreatic cancers, emphasizing theranostic applications. Key research directions include optimizing therapeutic efficacy, minimizing radiation toxicity, and exploring combination therapies to enhance tumor control. The lab also conducts detailed preclinical studies using xenograft models to evaluate biodistribution, dosimetry, and biological effects of radiopharmaceuticals.
Figures are computed from collected data and may differ slightly.
This study suggested the possible application of FAPI radioligand therapy in FAP-expressing pancreatic cancer. Further evaluation is necessary to find the best radionuclide with shorter half-life, as well as the combination with therapies targeting tumour cells directly.
We recently reported the dose-dependent therapeutic effect of <sup>211</sup>At-NaAt in differentiated thyroid cancer xenograft models. In the present study, we evaluated the radiation-induced toxicity of <sup>211</sup>At-NaAt using detailed hematological, biochemical, and histological analyses. Biodistribution of <sup>211</sup>At-NaAt was measured in normal ICR mice (n = 12), absorbed doses in the major organs were calculated. Groups of ICR mice (n = 60) were injected with 0.1 MBq or 1 MBq of <s
Abstract Purpose Fibroblast activation protein (FAP), which has high expression in cancer-associated fibroblasts of epithelial cancers, can be used as a theranostic target. Our previous study used 64 Cu and 225 Ac-labelled FAP inhibitors (FAPI-04) for a FAP-expressing pancreatic cancer xenograft imaging and therapy. However, the optimal therapeutic radionuclide for FAPI still needs to be further investigated. In this study, we evaluated the therapeutic effects of beta-emitter( 177 Lu)-labelled F
98 Purpose: Astatine(211At), an alpha-emitter with similar chemical properties to iodine, is expected to have a better therapeutic effect compared to 131I (beta-emitter). In the previous study, we revealed the dose-dependent therapeutic effect of 211At-NaAt solution by K1-NIS xenograft mice. In this study, we aimed to prove the better therapeutic effect of 211At-NaAt than 131I-NaI in differentiated thyroid cancer model. Methods: Colony assay and DNA double-strand break (DSB) assay were performe
1224 Purpose: We have recently reported the dose-dependent therapeutic effect of 211At-NaAt in differentiated thyroid cancer xenograft models. In this study, we evaluated the radiation-induced toxicity of 211At-NaAt using detailed hematological, biochemical, and histological analyses. Methods: Biodistribution of 211At-NaAt was measured in the normal ICR mice (n = 9, 38.2 ± 1.1 g), and the absorbed doses in the major organs were calculated. ICR mice groups (n = 60, 38.3 ± 1.9 g) were injected wi
1256 Purpose: An alpha-emitter, astatine(211At), can be used for the targeted alpha therapy of differentiated thyroid cancer. We have shown the dose-dependent treatment effect of 211At-NaAt solution using K1-NIS xenograft mice by single intravenous administration. In this study, we evaluated the therapeutic effect of repeated administration of 211At-NaAt solution to achieve the better tumor growth control against the radiation-induced toxicity of for the clinical application. Methods: Total of
Open papers in the app to read, cite, and organize with AI.
